Irazepine | 71735-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: Irazepine
• 英文别名: 7-chloro-5-(2-fluorophenyl)-1-(2-isothiocyanatoethyl)-3H-1,4-benzodiazepin-2-one
• CAS: 71735-92-7
• 化学式: C₁₈H₁₃ClFN₃OS
• 分子量: 373.8
• InChiKey: LTKSVYFAUMFQML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77.1
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• CD38-BINDING CD31 PEPTIDES AND USES THEREOF
  申请人：ENCEFA

  公开号：EP3943505A1

  公开（公告）日：2022-01-26

  The present invention relates to peptides derived from CD31, specifically binding to CD38; and their use in the prevention and/or treatment of diseases.

  本发明涉及从 CD31 衍生的肽，特别是与 CD38 结合的肽；以及它们在预防和/或治疗疾病中的用途。
• METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF
  申请人：Institut Curie

  公开号：EP3980057A1

  公开（公告）日：2022-04-13
• COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES
  申请人：Coda Biotherapeutics, Inc.

  公开号：US20190161529A1

  公开（公告）日：2019-05-30

  Compositions and methods are provided for modulating the activity of cells using engineered receptors, polynucleotide encoded engineered receptors, and gene therapy vectors comprising polynucleotides encoding engineered receptors. These compositions and methods find particular use in modulating the activity of neurons, for example in the treatment of disease or in the study of neuronal circuits.
• [EN] METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF<br/>[FR] MÉTHODES DE PRODUCTION DE MONOMÈRES ET D'OLIGOMÈRES DE LA SOUS-UNITÉ B DE LA TOXINE DE SHIGA (STXB), ET LEURS UTILISATIONS
  申请人：INST CURIE

  公开号：WO2020245321A1

  公开（公告）日：2020-12-10

  The present invention relates to a method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods described herein are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
• [EN] DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF<br/>[FR] LIPOPOLYSACCHARIDES (LPS) DÉTOXIFIÉES, LPS NATURELLEMENT NON TOXIQUES, ET LEURS UTILISATIONS
  申请人：HEPHAISTOS PHARMA

  公开号：WO2021180972A1

  公开（公告）日：2021-09-16

  The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being: - devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and - substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group. It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.